In Vitro Perfusion Studies on Human Umbilical Arteries: I. Vasoactive Effects of Serotonin, PGF<sub>2α</sub> and PGE<sub>2</sub>

Bjøro, Kristian; Stray‐Pedersen, Sverre

doi:10.3109/00016348609157359

Cited by 47 publications

(29 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in accordance with our earlier reports on the effect of serotonin on umbilical arteries from uncomplicated term pregnancies [3,14]. This transient pressure decrease seems to depend on the endothelium since the response disappears in preparations in which the endothelium is removed [14].…”

Section: Discussionsupporting

confidence: 81%

“…Haugen/Rognerud electrolyte solution was employed which contained NaCl 125 mmol/ l, KCl 4 mmol/l, CaCl 2 2 mmol/l, MgCl 2 1 mmol/l, NaHCO 3 22 mmol/l, NaH 2 PO 4 0.3 mmol/l, Na 2 HPO 4 1.7 mmol/l and glucose 5.6 mmol/l. Both solutions were equilibrated with a gas mixture of 5% O 2 , 5% CO 2 and 90% N 2 keeping a constant pH of about 7.40.…”

Section: Perfusion Procedures and Drug Administrationmentioning

confidence: 99%

“…At such a flow rate the pulse frequency created by the peristaltic pump was 100-120/min. The perfusion was carried out in a recirculating fashion until the start of drug infusion whereafter non-recirculating perfusion was employed [3].…”

Section: Perfusion Procedures and Drug Administrationmentioning

confidence: 99%

“…serotonin which is released from platelets during aggregation. In umbilical arterial strips serotonin induces a monophasic constrictory response [2], and in in vitro perfused arterial preparations from uncomplicated term pregnancies this autacoid produces a biphasic pressure response dominated by a pressure increase preceded by a small transient vasodilatation [3].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Doppler Flow Velocity Waveforms and Vasoactive Effects of Serotonin in Human Umbilical Arteries

Haugen

Rognerud²

2001

Gynecol Obstet Invest

View full text Add to dashboard Cite

The vasoactive effect of serotonin was investigated by in vitro perfusion in human umbilical arteries in which antenatal Doppler ultrasound examination revealed abnormal velocity waveforms. The results were compared to those obtained in preparations from normotensive uncomplicated term pregnancies as well as from preterm deliveries in which antenatal Doppler ultrasound examination showed normal velocity waveforms related to gestational age. Serotonin induced a monophasic vasoconstriction or a biphasic pressure response with a transient pressure decrease succeeded by a constrictory response. In all groups serotonin induced a significant (p < 0.001) constrictory response, whereas no significant differences were observed between the groups. At a serotonin dose of 10^–7 mol/l, the frequency of preparations with a biphasic pressure response was significantly smaller in the preparations with abnormal diastolic flow as compared to the term control group (5/18 vs. 13/19, p = 0.02), but not significantly different from that of the preterm control group (3/9). The umbilical arterial responsiveness to serotonin does not seem to be dependent on antenatal Doppler velocity waveforms.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Perfusion Procedures and Drug Administrationmentioning

confidence: 99%

Section: Perfusion Procedures and Drug Administrationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Doppler Flow Velocity Waveforms and Vasoactive Effects of Serotonin in Human Umbilical Arteries

Haugen

Rognerud²

2001

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…32 It has been suggested that higher circulating levels of serotonin in the fetus might result in the vasoconstriction and smooth muscle cell proliferation that is characteristic of PPHN. 28,[33][34][35][36] That could explain why the association was slightly stronger when PPHN cases potentially attributable to other causes like prematurity were excluded from the analyses. If so, the outcome definition could explain some of the discrepancies among previous studies.…”

Section: Discussionmentioning

confidence: 99%

Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn

Huybrechts

Bateman

Palmsten

et al. 2015

Obstetrical &Amp; Gynecological Survey

View full text Add to dashboard Cite

IMPORTANCE-The association between selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and risk of persistent pulmonary hypertension of the newborn (PPHN) has been controversial since the US Food and Drug Administration issued a public health advisory in 2006. PARTICIPANTS-A total of 3 789 330 pregnant women enrolled in Medicaid from 2 months or fewer after the date of last menstrual period through at least 1 month after delivery. The source cohort was restricted to women with a depression diagnosis and logistic regression analysis with propensity score adjustment applied to control for potential confounders. CONCLUSIONS AND RELEVANCE-Evidence from this large study of publicly insured pregnant women may be consistent with a potential increased risk of PPHN associated with maternal use of SSRIs in late pregnancy. However, the absolute risk was small, and the risk increase appears more modest than suggested in previous studies. OBJECTIVE-To HHS Public AccessThe high pulmonary vascular resistance characteristic of fetal circulation fails to decrease at birth in 10 to 20 newborns in every 10 000 live births, resulting in right-to-left shunting of blood through fetal channels, diminished pulmonary blood flow, and profound hypoxemia. 1,2 Such persistent pulmonary hypertension of the newborn (PPHN) typically occurs in term or near-term infants and presents within hours of birth with severe respiratory failure requiring intubation and mechanical ventilation. 2 Persistent pulmonary hypertension of the newborn is associated with substantial morbidity and mortality: 10% to 20% of affected infants will not survive, and infants who survive face serious long-term sequelae including chronic lung disease, seizures, and neurodevelopmental problems due to both the hypoxemia and the aggressive treatments it often requires. 1,[3][4][5][6] In 2006, the US Food and Drug Administration (FDA) issued a public health advisory on a potential increased risk of PPHN associated with late pregnancy exposure to selective serotonin reuptake inhibitors (SSRIs) based on a single epidemiologic study that found a 6-fold increase in risk associated with SSRI use after the 20thweek of pregnancy. 7,8 Based on a review of additional studies with conflicting findings (2 studies reported an increase in risk, whereas 3 did not), the FDA concluded in 2011 that it was premature to reach any conclusion about a possible link between SSRI use in pregnancy and PPHN and updated the advisory accordingly. [9][10][11][12][13] The negative studies tended to be small, raising the possibility that they had insufficient power to detect an increased risk. 10,11 Given the ongoing controversy regarding the association between SSRI exposure in late pregnancy and the risk of this highly morbid pregnancy outcome, we examined the risk of The approach used for the development of our study cohort has previously been described in detail. 14 We identified all completed pregnancies in women aged 12 to 55 years and linked these pregnancies to ...

show abstract

Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn

Huybrechts

Bateman

Palmsten

et al. 2015

JAMA

216

125

View full text Add to dashboard Cite

IMPORTANCEThe association between selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and risk of persistent pulmonary hypertension of the newborn (PPHN) has been controversial since the US Food and Drug Administration issued a public health advisory in 2006. OBJECTIVE To examine the risk of PPHN associated with exposure to different antidepressant medication classes late in pregnancy. DESIGN AND SETTING Cohort study nested in the 2000-2010 Medicaid Analytic eXtract for 46 US states and Washington, DC. Last follow-up date was December 31, 2010.PARTICIPANTS A total of 3 789 330 pregnant women enrolled in Medicaid from 2 months or fewer after the date of last menstrual period through at least 1 month after delivery. The source cohort was restricted to women with a depression diagnosis and logistic regression analysis with propensity score adjustment applied to control for potential confounders.EXPOSURES FOR OBSERVATIONAL STUDIES SSRI and non-SSRI monotherapy use during the 90 days before delivery vs no use. MAIN OUTCOMES AND MEASURESRecorded diagnosis of PPHN during the first 30 days after delivery.RESULTS A total of 128 950 women (3.4%) filled at least 1 prescription for antidepressants late in pregnancy: 102 179 (2.7%) used an SSRI and 26 771 (0.7%) a non-SSRI. Overall, 7630 infants not exposed to antidepressants were diagnosed with PPHN (20.8; 95% CI, 20.4-21.3 per 10 000 births) compared with 322 infants exposed to SSRIs (31.5; 95% CI, 28.3-35.2 per 10 000 births), and 78 infants exposed to non-SSRIs (29.1; 95% CI, 23.3-36.4 per 10 000 births). Associations between antidepressant use and PPHN were attenuated with increasing levels of confounding adjustment. For SSRIs, odds ratios were 1.51 (95% CI, 1.35-1.69) unadjusted and 1.10 (95% CI, 0.94-1.29) after restricting to women with depression and adjusting for the high-dimensional propensity score. For non-SSRIs, the odds ratios were 1.40 (95% CI, 1.12-1.75) and 1.02 (95% CI, 0.77-1.35), respectively. Upon restriction of the outcome to primary PPHN, the adjusted odds ratio for SSRIs was 1.28 (95% CI, 1.01-1.64) and for non-SSRIs 1.14 (95% CI, 0.74-1.74). CONCLUSIONS AND RELEVANCEEvidence from this large study of publicly insured pregnant women may be consistent with a potential increased risk of PPHN associated with maternal use of SSRIs in late pregnancy. However, the absolute risk was small, and the risk increase appears more modest than suggested in previous studies.

show abstract

In Vitro Perfusion Studies on Human Umbilical Arteries: I. Vasoactive Effects of Serotonin, PGF_2α and PGE₂

Cited by 47 publications

References 10 publications

Doppler Flow Velocity Waveforms and Vasoactive Effects of Serotonin in Human Umbilical Arteries

Doppler Flow Velocity Waveforms and Vasoactive Effects of Serotonin in Human Umbilical Arteries

Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn

Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn

Contact Info

Product

Resources

About

In Vitro Perfusion Studies on Human Umbilical Arteries: I. Vasoactive Effects of Serotonin, PGF2α and PGE2

Cited by 47 publications

References 10 publications

Doppler Flow Velocity Waveforms and Vasoactive Effects of Serotonin in Human Umbilical Arteries

Doppler Flow Velocity Waveforms and Vasoactive Effects of Serotonin in Human Umbilical Arteries

Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn

Antidepressant Use Late in Pregnancy and Risk of Persistent Pulmonary Hypertension of the Newborn

Contact Info

Product

Resources

About

In Vitro Perfusion Studies on Human Umbilical Arteries: I. Vasoactive Effects of Serotonin, PGF_2α and PGE₂